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the most common major adverse events after percutaneous
coronary intervention (PCI) and is associated with increased
morbidity, short- and long-term mortality, and health-care
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In addition, the cumulative effect of these parameters on
renal function has been assessed with risk score models in a
number of studies (5,6). Thus far, prophylactic strategies for
CI-AKI are mainly related to preprocedural measurements
such as use of hydration, bicarbonate, and N-acetylcysteine,
which remain controversial (7,8). Deﬁnition of other risk
factors for CI-AKI, particularly procedural ones may help
broaden prophylactic strategies.
Recent studies have documented an association between
bleeding and mortality (short and long term) in patients
with acute coronary syndromes (ACS) as well as in those
undergoing PCI (9,10). Bleeding complications are not
uncommon, but may be underrecognized, and prompt,
effective identiﬁcation and management after PCI remains
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1261a major challenge. This may have a deleterious impact on
prognosis, outcomes, and costs. Anemia is known to be an
independent predictor of CI-AKI (4), being one of the main
variables of the Mehran contrast-induced nephropathy risk
score (5). However, few previous studies or risk score
models have accounted for periprocedural bleeding as a risk
factor for the development of CI-AKI. If periprocedural
bleeding is strongly associated with CI-AKI incidence,
there may be a potential to reduce the latter by recognizing
and actively managing the extent of periprocedural bleeding.
The purpose of this study was to determine CI-AKI incidence
after PCI and to evaluate the impact of bleeding on CI-AKI
development.eGFR = estimated
glomerular ﬁltration rate
Hb = hemoglobin
MAP = mean arterial
pressure
PCI = percutaneous coronary
intervention
SBP = systolic blood
pressureMethods
Study population. The JCD-KICS (Japan Cardiovascular
Database-Keio Interhospital Cardiovascular Studies) is
a large, ongoing, prospective multicenter cohort registry
designed to collect clinical data on PCI patients. Patients
were enrolled at the time of their ﬁrst coronary event, and all
consecutive PCI procedures during the study period were
registered, including failure cases. The JCD-KICS began
enrolling patients in September 2008, and participating
hospitals collate patient data into an Internet-based database
system. The assigned clinical coordinators review the system
periodically to ensure that the reported data are accurately
and consistently documented. The majority of clinical vari-
ables in JCD-KICS were deﬁned according to the National
Cardiovascular Data Registry, which was sponsored by the
American College of Cardiology to conduct comparative
research to determine the factors that lead to disparities in
PCI management.
Before the launch of the JCD-KICS, information on
the objectives of the present study, its social signiﬁcance,
and an abstract were provided for clinical trial registration
with the University Hospital Medical Information
Network (UMIN000004736). The study protocol was
approved by the institutional review board at each site.
As of December 31, 2011, 12 hospitals had contributed
data on 4,117 consecutive PCI procedures. An interventional
team performed PCIs according to standard clinical practice
via the femoral or radial approach. Supportive pharmaco-
logical therapies, mechanical support, contrast medium dose
(nonionic low osmolar), and angioplasty technique were
left to the discretion of the operator, according to each
institution’s clinical protocols and international guidelines.
Patients with estimated glomerular ﬁltration rate (eGFR)
<60 ml/min received intravenous hydration; however, no
patients received bicarbonate or N-acetylcysteine in this
study. Nephrotoxic medications such as biguanide or
nonsteroidal anti-inﬂammatory drugs were stopped before
elective cases and after admission in emergent cases. For the
present analysis, 1,471 patients were excluded because of
missing initial or peak serum creatinine (Cr) and/or hemo-
globin (Hb) (n ¼ 974) levels or incomplete data on sex,age, or death (n ¼ 216). Further-
more, patients with cardiopulmo-
nary arrest and/or cardiogenic
shock (n ¼ 169), those on dialysis
(n ¼ 40), and those with Cr
level 8.0 mg/dl or Hb <7 g/dl
(n ¼ 72) were also excluded
(Fig. 1). We divided the remain-
ing 2,646 consecutive patients
into 5 groups according to the
change in Hb after versus before
PCI. Patients without a decrease
in Hb (group A) and patients
with decreased Hb level: <1 g/dl
(group B), 1 to<2 g/dl (group C),
2 to <3 g/dl (group D), and
>3 g/dl (group E).
Patient demographic data
included risk factors for coronary
artery disease, presenting condi-
tion at the time of PCI (elective or
urgently/emergently for ACS),
and procedural data.
The recommended antiplatelet regimen was long-term
81 to 162 mg aspirin daily and a thienopyridine (200 mg
ticlopidine or 75 mg clopidogrel daily) for at least 1 year after
drug-eluting or bare metal stent implantation for patients
presenting with ACS. For patients who received a bare metal
stent for non-ACS, a thienopyridine was given for a mini-
mum of 1 month and ideally up to 12 months. During PCI,
unfractionated heparin was used for anticoagulation to ach-
ieve and maintain an activated clotting time of 250 to 300 s.
We investigated all-cause death as well as the composite
of heart failure, cardiogenic shock, and death. In addition,
we investigated the rates of complications such as peri-
procedural myocardial infarction, heart failure, cardiogenic
shock, stroke, tamponade, new requirement for hemodial-
ysis, need for blood transfusion, and major bleeding.
Deﬁnitions. CI-AKI was deﬁned according to the estab-
lished deﬁnitions in the literature as an increase in serum
Cr 0.5 mg/dl or 25% above baseline values at 48 h after
administration of contrast media when no other major
kidney insult was identiﬁed. If >1 post-PCI Cr level was
measured, the highest value was used for CI-AKI calcula-
tion. Major bleeding was deﬁned as: 1) bleeding requiring
a blood transfusion; 2) a decrease in Hb 3.0 g/dl from any
location, including percutaneous entry site, retroperitoneal,
gastrointestinal, genitourinary, and other/unknown location;
and 3) procedural intervention/surgery at the bleeding site
to reverse/stop or correct the bleeding (such as surgical
closures/exploration of the arteriotomy site, balloon angio-
plasty to seal an arterial tear, or endoscopy with cautery of
a gastrointestinal bleed). The latter deﬁnition is equivalent
to Bleeding Academic Research Consortium type 3 bleeding
(11). Minor bleeding was deﬁned as all other clinically
signiﬁcant bleeding not meeting the deﬁnition for major
PCI 2008 Sep. – 2011 Dec. from JCD-KICS 
Multicenter registry N=4,117 
Excluded (n=1,471) 
·
·
·
·
·
Missing initial or peak serum creatinine and/or hemoglobin (n=974) 
 Incomplete data of gender, age, or death (n=216) 
 Cardiopulmonary arrest and/or cardiogenic shock (n=169) 
 Dialysis (n=40) 
 Cr level 8.0 mg/dL or Hb <7 g/dL (n=72)
CI-AKI study population N=2,646 
Figure 1 Flowchart of Study Progress
For the present study, 1,471 patients were excluded because of missing initial or peak serum creatinine (Cr) and/or hemoglobin (Hb) (n ¼ 974) or incomplete data on sex, age,
or death (n ¼ 216). Patients with cardiopulmonary arrest and/or cardiogenic shock (n ¼ 169), those on dialysis (n ¼ 40), and those with Cr level 8.0 mg/dl or Hb level <7 g/dl
(n ¼ 72) were also excluded. CI-AKI ¼ contrast-induced acute kidney injury; JCD-KICS ¼ Japan Cardiovascular Database-Keio Interhospital Cardiovascular Studies; PCI ¼
percutaneous coronary intervention.
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Consortium type 2 bleeding.
CKD was deﬁned as a baseline eGFR <60 ml/min/
1.73 m2. The eGFR was calculated using serum Cr levels
and the Modiﬁcation of Diet in Renal Disease study
equation (12).
Statistical analysis. Baseline characteristics were compared
between the patients with CI-AKI and those without CI-AKI.
Continuous variables are expressed as mean  SD unless
otherwise speciﬁed. Categorical variables are expressed as
absolute values and percentages. The independent-samples
t test and analysis of variance (ANOVA) were used for
comparison of means of continuous variables. The Pearson
chi-square test was used for comparison of categorical vari-
ables. Multivariable logistic regression analysis was used to
assess variables independently associated with CI-AKI. All p
values are 2-sided. Results were considered to be statistically
signiﬁcant at a p value <0.05. All statistical analyses were
performed with SPSS version 19.0.0 (SPSS Inc., Chicago,
Illinois).Results
Clinical characteristics. Of the 2,646 patients in the study
population, 315 (12%) experienced CI-AKI after PCI.
Baseline demographic, clinical, and angiographic character-
istics, as well as main procedural data at the time of primary
PCI are listed in Table 1. In the overall population, the
mean age was 67.6 years, and 80% were males. The mean
baseline serum Cr level was 0.9  0.4 mg/dl. There were
signiﬁcant clinical and procedural differences betweensubjects with and without CI-AKI. As seen in Table 1, the
mean baseline serum Cr level was higher with CKD
observed more frequently in the CI-AKI group. Patients
with CI-AKI also had lower left ventricular ejection fraction
and more often had a history of heart failure than patients
without CI-AKI. Patients with CI-AKI more frequently
underwent urgent/emergent PCI and had more complex
coronary disease (3-vessel coronary artery disease, intra-aortic
balloon pump use during PCI, and type C lesions). Finally,
total ﬂuoroscopy time was longer in the CI-AKI group.
Multivariate analysis. Variables independently associated
with CI-AKI after PCI are shown in Table 2. CI-AKI was
most strongly associated with CKD. Patients who under-
went PCI in urgent or emergent settings or presented with
heart failure symptoms of New York Heart Association
functional class of III or higher or ST-segment elevation
myocardial infarction were also strongly correlated with
CI-AKI. CI-AKI was likely to develop in patients with
major bleeding with an odds ratio of 2.23 (95% conﬁdence
interval: 1.37 to 3.63; p ¼ 0.001).
In-hospital complications. Five percent of patients who
experienced CI-AKI died in the hospital, compared with 1%
of patients without CI-AKI (p < 0.001) (Table 3). The rate
of a composite of heart failure, cardiogenic shock, and death
was also signiﬁcantly higher in the CI-AKI group compared
with the non–CI-AKI group (17% vs. 3%, p < 0.001).
Patients who experienced CI-AKI had a much higher
incidence of complications such as periprocedural myocardial
infarction, heart failure, cardiogenic shock, new requirement
for hemodialysis, need for blood transfusion, and major
bleeding after PCI (31% vs. 11%, p < 0.001). Patients in
Table 1 Baseline, Lesion, and Procedural Characteristics
CI-AKI
(n ¼ 315)
No CI-AKI
(n ¼ 2,331) p Value
Age, yrs 68.0  11.1 67.5  10.8 0.510
Male 234 (74) 1,873 (80) 0.014
Hypertension 225 (71) 1,664 (71) 1.000
Diabetes mellitus 129 (41) 940 (40) 0.854
Dyslipidemia 195 (62) 1,588 (68) 0.029
Chronic kidney disease 54 (17) 261 (11) 0.008
Smoking 123 (39) 778 (33) 0.050
Hemoglobin, g/dl 13.4  2.3 13.6  1.8 0.103
Creatinine, mg/dl 1.0  0.8 0.9  0.3 0.004
LVEF, % 50.6  12.5 56.5  13.3 <0.001
Previous myocardial infarction 42 (13) 538 (23) 0.001
Previous heart failure 33 (11) 145 (6) 0.008
Cerebrovascular disease 30 (10) 174 (8) 0.215
Peripheral artery disease 13 (4) 165 (7) 0.054
COPD 7 (2) 71 (3) 0.593
Previous PCI 50 (16) 782 (34) 0.001
Previous CABG 12 (4) 114 (5) 0.481
PCI indication
Elective 68 (22) 1,233 (53) <0.001
Urgent 99 (31) 576 (25) 0.013
Emergent 148 (47) 522 (22) <0.001
Lesion site
LMT 25 (8) 225 (10) 0.328
Proximal LAD 132 (42) 845 (36) 0.051
TRI 36 (11) 612 (26) 0.001
TFI 268 (85) 1,648 (71) 0.001
IABP 17 (5) 37 (2) 0.001
3VD 100 (32) 551 (24) 0.002
Type C 98 (31) 587 (25) 0.028
Total ﬂuoroscopy time 34.0  26.6 30.9  21.1 0.029
Values are mean  SD or n (%).
CABG ¼ coronary artery bypass graft; CI-AKI ¼ contrast-induced acute kidney injury;
COPD ¼ chronic obstructive pulmonary disease; IABP ¼ intra-aortic balloon pump; LAD ¼ left
anterior descending; LMT ¼ left main trunk; LVEF ¼ left ventricular ejection fraction;
PCI ¼ percutaneous coronary intervention; TFI ¼ transfemoral intervention; TRI ¼ transradial
intervention; 3VD ¼ 3-vessel disease.
Table 3 In-Hospital Complications
Complication
CI-AKI
(n ¼ 315)
No CI-AKI
(n ¼ 2,331) p Value
Death 17 (5) 15 (1) <0.001
Heart failure, shock, death 52 (17) 66 (3) <0.001
Complication 98 (31) 251 (11) <0.001
Myocardial infarction 18 (6) 68 (3) 0.016
Shock 23 (7) 26 (1) <0.001
Hemodialysis 21 (7) 0 (0) <0.001
Blood transfusion 22 (7) 38 (2) <0.001
Major bleeding 34 (11) 84 (4) <0.001
Values are n (%).
CI-AKI ¼ contrast-induced acute kidney injury.
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rates of major bleeding and blood transfusion compared with
those in whom CI-AKI did not develop. Seven percent of
patients who experienced CI-AKI required hemodialysisTable 2 Independent Correlates of CI-AKI After PCI
Variable
Odds
Ratio
95% Conﬁdence Limits
p ValueLower Upper
Major bleeding 2.23 1.37 3.63 0.001
Chronic kidney disease 4.20 2.08 8.48 <0.0001
Previous heart failure 1.65 1.01 2.71 0.048
STEMI 2.15 1.42 3.27 <0.0001
Non-STEMI 1.64 1.02 2.64 0.041
NYHA functional class III 2.53 1.67 3.85 <0.0001
Urgent PCI 3.23 2.13 4.91 <0.0001
Emergent PCI 3.88 2.37 6.36 <0.0001
3VD 1.44 1.08 1.92 0.001
NYHA ¼ New York Heart Association; STEMI ¼ ST-segment elevation myocardial infarction; other
abbreviations as in Table 1.treatment compared with no patients in the non–CI-AKI
group (p < 0.001).
Severity of Hb decrease and incidence of CI-AKI, major
bleeding, and other complications. A signiﬁcant positive
association between the severity of the decrease in Hb and
event rate was observed in our study population. During the
48 h after the procedure, the following events were observed:
315 CI-AKI cases overall (12%), 18 (6%) in group A,
57 (8%) in group B, 93 (11%) in group C, 83 (17%) in
group D, and 64 (26%) in group E (p < 0.001) (Table 4,
Fig. 2). Moreover, signiﬁcantly increased rates of any
complications and death were observed in those patients
with more severe decrease in Hb level. Furthermore, the
incidence of major bleeding signiﬁcantly increased with a
greater decrease in Hb drop (p < 0.001). On the other hand,
patients with minor bleeding showed a nonsigniﬁcant trend
of the development of CI-AKI (odds ratio ¼ 2.22, 95%
conﬁdence interval: 0.62 to 7.93; p ¼ 0.388) (Online
Table 1).
Discussion
The major ﬁndings of the present study were as follows:
1) patients who experienced periprocedural bleeding had
a higher likelihood of the development of CI-AKI and
2) CI-AKI incidence correlated closely with bleeding
severity. Patients in whom CI-AKI developed had poorer
in-hospital outcomes, in both all-cause death and the
composite of heart failure, cardiogenic shock, and death,
than patients in whom CI-AKI did not develop.
An important ﬁnding of our study was that CI-AKI
incidence and in-hospital complications were signiﬁcantly
associated with bleeding severity. Several studies have
analyzed the relationship between CI-AKI incidence and
baseline Cr level (1), CI-AKI incidence in elective versus
emergent PCI settings (13); however, few studies have
examined the relationship between bleeding severity and
CI-AKI incidence. Previous studies have suggested an
association between bleeding after PCI and late mortality.
Applegate et al. (14) observed Thrombolysis In Myocardial
Infarction bleeding grade to be an independent predictor
of death at 1 year in a large population of 3,931 patients.
Romaguera et al. (15) reported that patients with vascular
Table 4 In-Hospital Complications and Degree of Hemoglobin Decrease
Group
p Value
A
(n ¼ 290)
B
(n ¼ 755)
C
(n ¼ 870)
D
(n ¼ 487)
E
(n ¼ 244)
CI-AKI 18 (6) 57 (8) 93 (11) 83 (17) 64 (26) <0.001
Death 1 (0) 3 (0) 11 (1) 8 (2) 9 (4) 0.001
Heart failure, shock, death 5 (2) 13 (2) 34 (4) 31 (6) 35 (14) <0.001
Complication 19 (7) 56 (7) 92 (11) 82 (17) 100 (41) 0.001
MI 8 (3) 22 (3) 29 (3) 17 (4) 10 (4) 0.884
Shock 1 (0) 5 (1) 10 (1) 14 (3) 19 (8) <0.001
Hemodialysis 1 (0) 4 (1) 5 (1) 7 (1) 4 (2) 0.152
Blood transfusion 1 (0) 6 (1) 20 (2) 15 (3) 18 (7) <0.001
Major bleeding 2 (1) 10 (1) 17 (2) 20 (4) 69 (28) <0.001
Puncture site hematoma 2 (1) 6 (1) 8 (1) 10 (2) 21 (9) <0.001
Values are n (%).
CI-AKI ¼ contrast-induced acute kidney injury; MI ¼ myocardial infarction.
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increased risk of death at 1 year.
Our study, however, conﬁrms the importance of the
volume of periprocedural blood loss as a risk factor for
patients experiencing CI-AKI. Even small absolute changes
in Hb level were found to be associated with signiﬁcantly
increased rates of both CI-AKI and in-hospital complica-
tions. Does this change in Hb level always indicate bleeding?
Previsdomini et al. (16) described the alteration of Hb level
of nonbleeding patients with ACS during the ﬁrst 24 h
in the intensive care unit. In this series, the extent of Hb
decrease was only 1.27  1.00 g/dl, which is far from our
bleeding threshold of 3 g/dl. Furthermore, Svensén et al.
(17) described that hemodilution with ﬂuid resuscitationGroup A 
In
ci
de
nc
e 
(%
)
Group B Group C Group D Group E 
0
10
20
30 Heart Failure + Shock + Death 
CI-AKI 
Major Bleeding 
Figure 2
Correlation Between the Degree of Hb Decrease
and Clinical Events
Incidence of composite of heart failure, shock, and death (blue); contrast-induced
acute kidney injury (CI-AKI) (red); and major bleeding (green) in patients in
groups A through E. Hb ¼ hemoglobin.requires a large amount of Ringer’s solution, more speciﬁ-
cally, a mean volume of 5.9  0.8 l.
In the literature, an acute decrease in Hb is reported in
severe AKI cases for which hemodialysis is required (18). In
their report, a dramatic drop in Hb concentration occurred
several days after the onset of AKI and was suggested due to
decreased erythropoietin levels associated with AKI. How-
ever, in our studies, most of the patients in whom CI-AKI
developed had a modest increase in Cr level, and only 7%
of the patients in whom CI-AKI developed required
hemodialysis. Moreover, we collected data on post-PCI Hb
level within 72 h after the procedure (i.e., during the acute
phase). The deﬁnition of CI-AKI used (i.e., an increase in
serum Cr at 48 h after contrast media administration)
renders it less likely that renal anemia contributed to a
decrease in Hb.
Major bleeding may lead to hemodynamic compromise. It
is important to distinguish whether CI-AKI is caused by
hemodynamic compromise or by signiﬁcant blood loss. In
this study, we have excluded patients presenting with
cardiogenic shock. Moreover, we performed 1-way ANOVA
of systolic blood pressure (SBP), mean arterial pressure
(MAP), and diastolic blood pressure (DBP) before and after
PCI among groups A through E. Blood pressure change was
also analyzed. There were no signiﬁcant differences in SBP,
MAP, or DBP before PCI among the 5 groups (p ¼ 0.151,
p ¼ 0.158, and p ¼ 0.213, respectively) (Online Table 2).
Moreover, a change in SBP, MAP, and DBP also showed
no signiﬁcant differences among the 5 groups (p ¼ 0.126,
p ¼ 0.736, and p ¼ 0.592, respectively). Nonetheless,
signiﬁcantly increased rates of CI-AKI and bleeding events
(p < 0.01 and p < 0.01, respectively) were observed in those
patients with more severe decrease in Hb level. On the other
hand, there were 49 cases (1.9%) in the study population of
patients with a signiﬁcant compromise of hemodynamics
during PCI, which we have deﬁned as cardiogenic shock. In
patients with cardiogenic shock CI-AKI developed signiﬁ-
cantly more frequently compared with patients in whom it
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signiﬁcantly increased rates of cardiogenic shock were
observed in those patients with more severe decrease in Hb
level (Table 4).
Another major risk factor of CI-AKI is the volume of
contrast media. We performed 1-way ANOVA comparisons
of contrast volume among the 5 groups A through E. There
were no signiﬁcant differences in contrast volume among
the 5 groups (p ¼ 0.519) (Online Table 2). Moreover,
contrast volume adjusted for body mass index also showed
no signiﬁcant differences among the 5 groups (p ¼ 0.079).
Against the background of the extensive literature on
CI-AKI (1,2,5,6,19,20), which has been the subject of
numerous comprehensive reviews (21,22), the present study
provides additional clinical insight. In most catheterization
laboratories, baseline Cr is currently assessed before PCI;
therefore, interventional cardiologists can predict the risk of
CI-AKI developing before the procedure, especially in
elective cases. Those patients predicted to be at high risk of
CI-AKI should undergo additional preventive measures and
staged procedures, and perioperative blood loss should be
minimized. In such cases, performing PCI via a transradial
approach would be preferred because the risk of bleeding
is signiﬁcantly lower compared with the transfemoral
approach (23,24). In a large Canadian registry, Vuurmans
et al. (25) reported signiﬁcantly higher incidence of CKD
within 6 months of the cardiac procedure performed via
the transfemoral approach compared with the transradial
approach. Our study population also shows a higher inci-
dence of CI-AKI with transfemoral intervention; however,
most of the urgent or emergent cases were performed with
transfemoral intervention; therefore, further conﬁrmation is
needed of whether performing PCI via the transradial
approach decreases the incidence of CI-AKI.
Study limitations. Our study has the inherent limitations
of its retrospective design, although the data were collected
prospectively. Because the operators were not blinded to the
clinical and laboratory information including baseline Cr
and Hb levels, additional measures to prevent CI-AKI
might have been undertaken in select patients. Due to the
limited availability of data ﬁelds, data on the volume of
contrast media, accurate periprocedural hydration volume,
presence of proteinuria, urine output, and use of nephrotoxic
medications were not available in our database. Although
serum Cr levels were checked routinely after PCI, some
patients in whom increased serum Cr developed after
hospital discharge may have been missed. The type of AKI
(hemodynamic, ischemic, nephrotoxic, or atheroembolic)
could not be determined precisely. Because of the nature of
both the patients and procedures performed, AKI was
assumed to be multifactorial. Furthermore, because of
methodological limitations inherent to retrospective registry
analyses, our data cannot establish a deﬁnite etiological link
between worsening renal function after PCI and the
increased risk of major adverse cardiorenal events and death.
Moreover, we could not demonstrate that bleeding precedesAKI in a vast majority of cases. Our ﬁndings should be
conﬁrmed in larger multicenter trials.
Conclusions
Periprocedural bleeding is signiﬁcantly associated with
CI-AKI, CI-AKI incidence correlates with bleeding se-
verity, and patients who experience CI-AKI after PCI are at
very high risk of in-hospital death.
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For supplemental material including a list of investigators and clinical
coordinators as well as supplemental tables, please see the online version
of this article.
